重症幼年皮肌炎的治疗进展  

Therapeutic advances on juvenile dermatomyositis

作　　者：孙广超 曾华松 

机构地区：[1]广州市妇女儿童医疗中心儿童院区过敏免疫风湿病科,510120

出　　处：《中国小儿急救医学》2013年第3期248-252,共5页Chinese Pediatric Emergency Medicine

基　　金：国家863计划（012AA02A513）;国家人事部留学归国人员启动基金（200499）;广州市医药卫生科技项目（20121A011055）

摘　　要：当前幼年皮肌炎的治疗以皮质激素及各种传统的免疫抑制剂（如甲氨蝶呤和硫唑嘌呤）为主。静脉注射免疫球蛋白是一种有效的短期治疗方法。环孢霉素和他克莫司对皮肌炎包括肺间质病变有效，而霉酚酸酯则对多发性肌炎和难治性皮肌炎有效。生物制剂的疗效有待于进一步验证。The current management for juvenile dermatomyositis includes the initial use of corticoste- roids followed by various conventional second-line treatments such as methotrexate and azathioprine. Intravenous immunoglobulin is a reasonable short-term treatment with proven benefit. Cyclosporine or tacrolimus have shown efficacy in juvenile dermatomyositis including those patients with interstitial lung disease, whereas mycophenolate mofetil is effective in both polymyositis and refractory dermatomyositis. The curative effect of biological agents needs to be further studied.

关 键 词：幼年皮肌炎 糖皮质激素 免疫抑制剂 生物制剂 

分 类 号：R725.9[医药卫生—儿科]